N-[4-hydroxy-3-(2-methyl-2H-pyrazol-3-yl)phenyl]acetamide | 839714-88-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-[4-hydroxy-3-(2-methyl-2H-pyrazol-3-yl)phenyl]acetamide
• 英文别名: N-(4-hydroxy-3-(1-methyl-1H-pyrazol-5-yl)phenyl)acetamide；N-(4-hydroxy-3-(2-methyl-2H-pyrazol-3-yl)phenyl)acetamide；N-[4-hydroxy-3-(2-methylpyrazol-3-yl)phenyl]acetamide
• CAS: 839714-88-4
• 化学式: C₁₂H₁₃N₃O₂
• 分子量: 231.254
• InChiKey: AASANMDYWUJJEY-UHFFFAOYSA-N

物化性质

• 沸点：
  487.9±40.0 °C(Predicted)
• 密度：
  1.27±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  67.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-[4-hydroxy-3-(2-methyl-2H-pyrazol-3-yl)phenyl]acetamide 在 sodium hydroxide 、 水 、 caesium carbonate 作用下， 以 甲醇 、 异丁酰胺 为溶剂， 反应 3.5h， 生成 3-(2-methyl-2H-pyrazol-3-yl)-4-(2-methyl-2-nitropropoxy)aniline
  参考文献：
  名称：

  WO2007/136703

  摘要：

  公开号：
• 作为产物：
  描述：

  2-羟基-5-乙酰氨基苯乙酮 在 三氟化硼乙醚 作用下， 以 甲醇 、 异丙醇 为溶剂， 反应 20.0h， 生成 N-[4-hydroxy-3-(2-methyl-2H-pyrazol-3-yl)phenyl]acetamide
  参考文献：
  名称：

  WO2007/136689

  摘要：

  公开号：

文献信息

• [EN] DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERTO<br/>[FR] DERIVES DE DIARYL ET ARYLHETEROARYL UREE UTILISES EN TANT QUE MODULATEURS DU RECEPTEUR DE LA SEROTONINE 5-HT2A UTILES POUR LA PROPHYLAXIE ET LE TRAITEMENT DE TROUBLES ASSOCIES A CE DERNIER
  申请人：ARENA PHARM INC

  公开号：WO2005012254A1

  公开（公告）日：2005-02-10

  The present invention relates to certain pyrazole derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the prophylaxis or treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or a symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders and the like. The present invention also relates to the method of prophylaxis or treatment of 5-HT2A serotonin receptor mediated disorders in combination with a dopamine D2 receptor antagonist such as haloperidol, administered separately or together.

  本发明涉及某些Formula (I)的吡唑衍生物及其药物组合物，可调节5-HT2A 5-羟色胺受体的活性。该类化合物及其药物组合物用于预防或治疗血小板聚集、冠状动脉疾病、心肌梗死、短暂性缺血性发作、心绞痛、中风、心房颤动、减少血凝块形成风险、哮喘或其症状、激动或症状、行为障碍、药物诱导的精神病、兴奋性精神病、吉尔·德·拉·图雷特综合征、躁狂症、器质性或NOS精神病、精神病性障碍、精神病、急性精神分裂症、慢性精神分裂症、NOS精神分裂症及相关疾病、睡眠障碍、睡眠障碍、糖尿病相关疾病等的方法。本发明还涉及预防或治疗5-HT2A 5-羟色胺受体介导的疾病的方法，结合多巴胺D2受体拮抗剂如氟哌啶醇，分别或联合给药。
• Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
  申请人：Teegarden Bradley

  公开号：US20050080124A1

  公开（公告）日：2005-04-14

  The present invention relates to certain pyrazole derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT 2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the prophylaxis or treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or a symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders and the like. The present invention also relates to the method of prophylaxis or treatment of 5-HT 2A serotonin receptor mediated disorders in combination with a dopamine D2 receptor antagonist such as haloperidol, administered separately or together.

  本发明涉及某些式（I）的吡唑衍生物及其药物组合物，该组合物调节5-HT2A血清素受体的活性。该化合物及其药物组合物适用于预防或治疗血小板聚集、冠状动脉疾病、心肌梗死、短暂性脑缺血发作、心绞痛、中风、心房颤动、降低血栓形成风险、哮喘或其症状、激动或症状、行为障碍、药物诱导性精神病、兴奋性精神病、Gilles de la Tourette综合症、躁狂障碍、有机或非器质性精神病、精神病性障碍、急性精神分裂症、慢性精神分裂症、非特异性精神分裂症及相关疾病、睡眠障碍、糖尿病相关疾病等预防或治疗的方法。本发明还涉及与多巴胺D2受体拮抗剂（如氟哌啶醇）联合使用的5-HT2A血清素受体介导的疾病的预防或治疗方法，可以单独或联合使用。
• CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PHENYL-PYRAZOLES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR
  申请人：Gharbaoui Tawfik

  公开号：US20100234380A1

  公开（公告）日：2010-09-16

  The present invention relates to processes for preparing phenyl-pyrazoles of Formula (I) and salts and pharmaceutical compositions thereof, useful as modulators of 5-HT 2A serotonin receptor activity. The present invention also relates to intermediates used in the processes, and their preparation. The present invention also relates to crystalline forms of 5-HT 2A serotonin receptor modulators, compositions thereof and methods of using the same.

  本发明涉及制备式（I）的苯基吡唑及其盐和药物组合物的过程，它们可用作5-HT2A 5-羟色胺受体活性的调节剂。本发明还涉及用于该过程的中间体及其制备方法。本发明还涉及5-HT2A 5-羟色胺受体调节剂的晶体形式、其组合物及其使用方法。
• Primary Amines And Derivatives Thereof As Modulators Of The 5-HT2A Serotonin Receptor Useful For The Treatment Of Disorders Related Thereto
  申请人：TEEGARDEN BRADLEY

  公开号：US20120270861A1

  公开（公告）日：2012-10-25

  The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT 2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT 2A serotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.

  本发明涉及式(Ia)的某些化合物及其制药组合物，这些化合物调节5-HT2A 5-羟色胺受体的活性。这些化合物及其制药组合物用于治疗血小板聚集、冠状动脉疾病、心肌梗死、短暂性脑缺血发作、心绞痛、中风、心房颤动、血栓形成、哮喘或其症状、激动或其症状、行为障碍、药物诱导的精神病、兴奋性精神病、Gilles de la Tourette综合征、躁狂障碍、器质性或非器质性精神病、精神病、急性精神分裂症、慢性精神分裂症、非特异性精神分裂症及相关疾病以及睡眠障碍、糖尿病相关疾病、进行性多灶性白质脑病等方面的治疗方法。本发明还涉及与其他药物分别或同时给予的联合治疗5-HT2A 5-羟色胺受体相关疾病的方法。
• ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
  申请人：TEEGARDEN BRADLEY

  公开号：US20120295938A1

  公开（公告）日：2012-11-22

  The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT2A serotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.

  本发明涉及公式（Ia）的某些化合物及其制药组合物，其调节5-HT2A血清素受体的活性。该化合物和制药组合物针对的方法有助于治疗血小板聚集、冠状动脉疾病、心肌梗死、暂时性脑缺血发作、心绞痛、中风、心房颤动、血栓形成、哮喘或其症状、激动或其症状、行为障碍、药物诱发的精神病、兴奋性精神病、Gilles de la Tourette综合症、躁狂障碍、器质性或NOS精神病、精神病、急性精神分裂症、慢性精神分裂症、NOS精神分裂症及相关疾病、睡眠障碍、糖尿病相关疾病、进行性多灶性白质脑病等。本发明还涉及与其他药物分别或联合使用治疗5-HT2A血清素受体相关疾病的方法。